chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Cough; Shortness of Breath; Fatigue, Chills, Muscle or Body Aches, Headaches, New loss of taste or smell, Congestion or Runny Nose, Diarrhea; Vomiting. Prednisone (DELTASONE) 10 mg tablet; Take 2 tablets (20 mg total) by mouth 2 (two) times a day  for 4 days-Azithromycin (ZITHROMAX) 250 mg tablet; z pack. 500 mg day one 250 mg day 2-5. -Albuterol HFA (PROVENTIL;VENTOLIN) 90 mcg/actuation inhaler; Inhale 2 puffs every 6 (six) hours as needed  for wheezing for up to 7 days.
Developed tinnitus a short time after the second vaccine injection. No specific treatment has been administered yet.
This is a follow-up spontaneous report from a contactable consumer. A 69-years-old female patient received BNT162B2 (BNT162B2), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as UNKNOWN, SINGLE for COVID-19 immunization and tofacitinib citrate (XELJANZ XR), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication. The patient medical history and concomitant medications were not reported. The patient experienced sick on an unspecified date with outcome of unknown. No follow up attempts are possible; Information about Lot and batch number could not be obtained. No further information is expected.
Runny nose; Headache; Feeling weak; Ill/Sick; This is a spontaneous report from a contactable consumer or other non-health care professional (Patient's husband) via medical information team. A 67-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number and Expiration date not reported) via an unspecified route of administration in an unspecified anatomical location on an unspecified date in Feb2021 (at the age of 67-year-old) as single dose for COVID-19 immunisation. Medical history included influenza from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number and Expiration date not reported), via an unspecified route of administration in an unspecified anatomical location on an unspecified date as single dose for COVID-19 immunization. The patient has not been tested for Covid at the time of reporting. The patient experienced runny nose, headache and feeling weak on 07Jul2021, ill/sick in 2021. The patient reported that his wife started having symptoms last Wednesday, 07Jul2021 and she was getting better. States she was still somewhat weak from being sick but is improving. Though it was not confirmed yet, they believe that it was because of the delta variant of Covid.  Information about lot/batch number has been requested.
Approximately 3 hours After Administration  of flu shot patient was shopping And passed out. She was moved to a chair and recooperated. No other  symptoms reported before or After.
Pt called 6/9/2021 c/o covid vaccine side effects.. Pt stated pt got 2nd covid vaccine Pfizer 6/8/2021 and reports getting tingling and numbness on right leg and 3 toes in the middle of right foot after covid vaccination. Proceed covid 19 vaccine side effects questions and noted no emergency s/sx. Pt scheduled for urgent care visit for consultation.
Palpitations, elevated heart rate. Red Face. Red upper chest. Complained of lightheadedness and pre-syncopal.   HR radial 120 bpm, BP 145/91 with HR 111 with BP cuff.   Able to be released, feeling better.  Recheck of BP 137/84, HR 88 bpm.
approx 10 mins p/vax given pt got pale, listless & hypo-tonic; no LOC-P120,R24,T97 was evaluated by MD; pt observed for 1 hr & left clinic in good condition; f/u call 4 hrs later pt doing well;
fever after vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever after vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever after vaccine). At the time of the report, PYREXIA (fever after vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications provided. No treatment information was provided.   Reporter did not allow further contact
A week after I received the vaccine I developed crapping, extreme diarrhea, urgency to go to the bathroom. I went to the doctor who prescribed me steroids and is currently looking into changing my medications. She ordered two different types of of stool samples to check for bacteria and inflammation.
78-year-old male with a PMH significant for HTN, HLD, pulmonary emboli on ac (July 2021), vaccinated x 2 Moderna who was brought to the ER by his family due to altered mental status. He is a truck driver who recently came back, reports feeling very tired from the drive, parked in front of his house and fell asleep. This morning, he was woken up by his family and they found him altered. In the ER, NIH 1-for AMS on arrival, temperature 99.1 F, BP 142/86, HR 100, RR 18, pulse ox 96% on RA. CT head without acute intracranial abnormality, chronic white matter disease and unchanged foreign body on left temporal. CXR without acute cardiopulmonary disease and chronic elevation of the R-diaphragm. Labs significant for hypertriglyceridemia, mild AKI 1.4, UA negative, D-dimer 405, troponin negative, flu A/B negative but a covid-19 AG positive.
NEUROPATHY; ABNORMALITY IN T-CELL COUNT; STILL IN BAD SHAPE; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, 1 total, administered on an unspecified date in APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient was hospitalized for a week (date unspecified) and was diagnosed with neuropathy and abnormality with T-cell count. It was reported that the patient was still in bad shape. Laboratory data (dates unspecified) included: T-lymphocyte count (NR: not provided) Abnormal.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from still in bad shape, and the outcome of neuropathy and abnormality in T-cell count was not reported. This report was serious (Hospitalization Caused / Prolonged). This case, from the same reporter is linked to 20210540143.; Sender's Comments: V0:20210900314-COVID-19 VACCINE AD26.COV2.S-Neuropathy,  Abnormality in T-cell count- This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
10/25 at aprox 7pm I have some confusion & a hard time getting my words out. "Just not feeling right". By the am of 10/26 I had chills then sweats off and on. Body aches & felt like something was eating me from the inside out. Called Dr at 7:50pm. They said wait until 10/27 Am to come in. I felt better by then.
This spontaneous report as received from a licensed practical nurse refers to a 4 month old female patient. On 07-MAR-2014 the patient was vaccinated with a dose of ROTATEQ (lot number: J008507, exp.date: 31-MAR-2015) oral liquid orally (strength and dose not provided). No adverse effect has been observed or reported. Additional information has been requested.
Caller's sister, 57 years old, had the first dose of Pfizer Covid 19 vaccine and experienced dizziness three days later that lasted for two days and went away.This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 57 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious), outcome "recovered" described as "Caller's sister, 57 years old, had the first dose of Pfizer Covid 19 vaccine and experienced dizziness three days later that lasted for two days and went away.".  Additional Information: Caller is a 62-year-old female who received the second dose of the Pfizer Covid 19 vaccine Sunday.  Her arm was a bit sore. On Tuesday she started to get dizziness that has continued through today. She wanted to know if this is common. How long can it last. She read online has been reported as a side effect. She received Pfizer Lot #EN6198 for first dose and Pfizer Lot #EN6206 for second dose. Caller son in law, 30-year-old, received the second dose of the Pfizer Covid 19 vaccine on Sunday as well and was sick for 4 days: he had a bad headache, running a fever, 101.5 for a couple of days, very extremely tired from Sunday until today. Caller daughter, 30-year-old, received the Pfizer Covid 19 vaccine second dose on Sunday and experienced late that night chills, shaking, and felt faint. She took Tylenol, went to sleep, and was fine the next morning.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
Patient  was vaccinated at 2:15 at 2:20 she was given a Benadryl 50mg as she was complaining of difficult breathing, at 2 2:5 dhe presented whith bilateral wheezing, difficult breathing, ,stridor, heart 65 oxygen level 81, at2:30 we administered epinephrine 0.3mg and call the ambulance. patient immediately responded  wheezing cleared ,difficult breathing stoped  oxygen level increase to 100, heart rate increased to 100, she was taken to emergency room
Received PREVNAR 13 vaccine - a few hours after receiving left upper arm near injection site swelled up and is tender and warm to touch - informed to use ice and NSAID to help reduce swelling and to follow up w/MD if no improvement.
Throat tightness, swollen, SOB, rash on arms (Bi), back, did not go the DR (had second shot 1 week before) "I didn't want to miss training"
Arm began to become hot and swollen and was painful the evenening of the vaccine. There were also some small spots within the redness. The redness and swelling were not in the direct area in which the vaccine was delivered. The symptoms became more severe the next day, but started to improve slightly by the 2nd day after vaccine. When the patient came to the pharmacy, The pharmacist on duty looked at the area and suggested that she go to Urgent MD. Patient was headed to church and said she would go in the morning. I reccomended that she apply cold compresses and watch for any sudden changes or worsening of reaction.
Parent describes hyproresponsiveness and hypotonia for approximately 13 hrs following vaccine. was evaluated in the ER. Patient hospital to exam and in parents' opinion by 8:30 am the following day (<24 hours duration)  See attached for details
I had not had a menstrual cycle in 6 months. Two days after both my first and second shots, I got one. I have not had one since.
WHILE PATIENT WAS MONITORED POST VACCINATION , WITHIN 15 MIN, PATIENT FELT  WEAK  AND HAD VOMITING. EMERGENCY RESPONDERS WAS CALLED , PATIENT WAS TRANSPORTED TO EMERGENCY ROOM. ACCORDING TO PATIENT SHE WAS TREATED WITH FLUID INJECTION AND STOMACH MEDICINE FOR NAUSEA AND VOMITING.  AT THE ER, PHYSICAL CHECK UP AND BLOOD WORK WERE PERFORMED, NO ABNORMAL FINIDINGS. PATIENT WAS DISCHARGED TO HOME FEW HOURS LATER. HCP CALLED PATIENT NEXT MORNING FOR FOLLOW UP , PATIENT STATED SHE IS FINE  NO SYMPTOMS OF WEAK/NAUSEA/VOMITING.
On 17-AUG-2018, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (lot # R004689; expiration date: 29-NOV-2020) or (lot # R006689; expiration date: 29-NOV-2020) (dose and route of administration were not reported) for prophylaxis, which had a temperature excursion of 47 degrees F to 77 degrees F (56F) for 15 days on unspecified dates. There were no previous temperature excursions and no digital data logger involved in recording the temperature excursion. No adverse effects were reported. This is one of several reports from the same source; Sender's Comments: US-009507513-1808USA012996: US-009507513-1809USA006251: US-009507513-1809USA006252: US-009507513-1809USA006253: US-009507513-1809USA006254: US-009507513-1809USA006256: US-009507513-1809USA006257: US-009507513-1809USA006258: US-009507513-1809USA006259: US-009507513-1809USA006260: US-009507513-1809USA006261: US-009507513-1809USA006262: US-009507513-1809USA006263.
This spontaneous report as received from a licensed practical nurse and refers to an unspecified number of patients of unknown age and gender. On an unknown dates the patients were vaccinated with improperly stored doses of VARIVAX lot#: L029466, expiry: 06-AUG-2017. Excursions for VARIVAX lot#:L029466, expiry: 06-AUG-2017 (also included PROQUAD) occurred on multiple days were listed below: -12C for 16 hours, -12C for 8 hours, -13C for 8 hours, -12C for 16 hours, -12C for 8 hours, -12C for 23 hours and 45 minutes, -14C for 7 hours and 45 minutes, -13C for 32 hours, -11C for 11 days, -11C for 8 hours, -13C for 24 hours and 15 minutes, -13C for 24 hours, -12C for 25 hours, -13C for 8 hours, -13C for 24 hours, -12C for 72 hours, -13C for 25.5 hours, -14C for 16 hours, -12C for 88 hours, -12C for 48 hours, -12C for 72 hours, -12C for 98 hours, -12C for 23 hours and 45 minutes, -14C for 24 hours, -12C for 24 hours. No further details were provided. This is one of two reports received from the same source. Additional information has been requested.
Client felt light headed and dizzy approximately 3-5 minutes following vaccination.  Loss of consciousness, fell from chair in observation area. Regained consciousness approximately 1 min. later. Assisted to cot with legs elevated. Vitals obtained by on-site EMS. Vitals: @ 1605 HR 53, Spo298%, BP 159/88 initially. Continued to monitor last vitals 143/80, HR 56, SPO2 98%. Client denies ongoing dizziness or feeling faint. Client able to sit, stand, and walk without symptoms. Client left site in stable condition.
tetanus vaccine was given to a patient that with expiration date of 1/22/2023 with no reported adverse events; Initial information received on 20-Jul-2023 regarding an unsolicited valid  non-serious case received from a pharmacist.  This case involves an unknown age and unknown gender patient and expired Tetanus Toxoid was given to a patient with no reported adverse events.  The patient's past medical treatment(s), vaccination(s) and family history were not provided. It is unknown if the patient had any medical history, medical treatment (s), concomitant disease or risk factor.   On an unknown date, the patient received an unknown dose of suspect TETANUS TOXOID produced by unknown manufacturer (lot number: U6922AA, Expiry date: 22-Jan-2023) (With an unknown formulation, strength) via unknown route in unknown administration site for prophylactic vaccination (Immunisation).  On an unknown date, expired Tetanus toxoid was given to a patient with no reported adverse events (expired product administered) (latency: same day).  It is unknown if the patient experienced any additional symptoms/events  It is unknown if there were lab data/results available.  It was reported, expiration date of 1/22/2023 NDC 49281- 215-88, Lot: U6922AA. Please advise of step that should be taken to care for patient if detrimental.  Action taken: not applicable.  Outcome: Unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
immunocompromised patient received 0.25 ml as the third dose; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (immunocompromised patient received 0.25 ml as the third dose) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (immunocompromised patient received 0.25 ml as the third dose). At the time of the report, ACCIDENTAL UNDERDOSE (immunocompromised patient received 0.25 ml as the third dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No treatment information was provided.   Reporter did not allow further contact
24 hours post vax, the pt experienced a large red area approximately 15 cm. It was also noted that some discoloration like a bruise, uncomfortable, itchy, left arm. Also general malaise.
Swollen and puffy eyes. Some pain involved.  It is Sunday 2/7/21 at 01:15 hours and it is still ongoing.
Information has been received from a nurse concerning a 13 month old female who on 25-JAN-2008 was vaccinated with a dose of measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (rHA) (656527/0285U). Concomitant vaccinations were reported as varicella virus vaccine live (MSD) (657797/0846U). On 26-JAN-2008, the patient developed a fever of 102 degrees within 24 hours of receiving measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (rHA) and also experienced vomiting. As of 28-JAN-2008, the patient's body temperature was 100.8 degrees. The outcome was reported as recovering. Sought medical attention was reported as: Yes. There was no product quality complaint. Additional information has been requested.
Dizziness, Headache, Myalgia, Fever, LIGHTHEADEDNESS, REDNESS/SWELLING AT INJECTION SITE Narrative:
Rash, UrticariaPruritus, Purpura, Vitiligo over her entire body Narrative:  She had a rash the day after her second vaccine. She saw her doctor 4 days after her second vaccine and was diagnosed with Vitiligo. She has patches of discolored scarred skin throughout her entire body. This continues to cause her problems.
Headache, Fever, Rash, chills, pain at injection site, red, raised rash at injection site. Narrative:
Symptoms reported were itchiness on 10/19/17 by patient's Mom, then 10/20/17 patient had red upper left arm, came in to office to see Dr. Exam left upper arm had erythema extending over deltoid, some warmth, no drainage, Left shoulder full range of motion, no pain with movement. Treatment. Injection site reaction: warm compresses. Outcome: Follow up call to Mom, fully resolved by Sunday 10/22/17, no redness, no swelling, no symptoms.
She an a fever of over 102 all day on 6/4/2021 (day after 2nd dose) and then spiked to 103.4 at 11:30pm on 6/4/2021.  She still ran a fever of between 100 and 101 the 2nd day after the vaccination (6/5/2021).  Today 6/6/2021 the fever has come down to between 99 and 99.5.
Information has been received from a health professional concerning her daughter with psoriasis who on 30-MAY-2007 was vaccinated IM with the first dose of GARDASIL.  Concomitant therapy included topical creams and lotions (unspecified).  The patient received the second dose late on 31-Dec-2007.  It was reported that the patient experienced pain at the injection site after the 1st and 2nd dose.  Medical attention was sought in the office.  The patient was recovered day after the vaccination.  No product quality complaint was involved.  This is one of the multiple reports from the same source (WAES# 0802USA01954 and 0802USA01957).  Additional information has been requested.
The patient stated that she had swelling, soreness, and tenderness under her arm. I spoke with her again on 5/16/22 and she stated that it felt better and was subsiding. I told her if it continues or gets worse to call or go in to see her primary care doctor
0.25mL administered at the second dose of primary series; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (0.25mL administered at the second dose of primary series) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 ml. On 30-Dec-2021, the patient experienced UNDERDOSE (0.25mL administered at the second dose of primary series). On 30-Dec-2021, UNDERDOSE (0.25mL administered at the second dose of primary series) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications was not provided by the reporter. Treatment information was not provided.
Dizziness, lightheadedness, nausea, increased heart rate, feeling of over-fullness quickly (with many meals)
Joint ache; Arms aching at the site of injection; feeling tired; A spontaneous report was received from a healthcare professional concerning a 75-year-old, female consumer who received Moderna's COVID-19 vaccine and experienced arms aching at site of injection, joint ache and feeling tired after the vaccine.  The patient's medical history, as provided by the reporter, included a bladder instillation and cystoscopy. Concomitant medications reported included betamethasone acetate/betamethasone sodium phosphate.   On 30 Dec 2020 at 0700AM, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025L20A) intramuscularly for prophylaxis of COVID-19 infection.     On 29 Dec 2020, the patient underwent a cystoscopy for a prior bladder instillation procedure. During, the cystoscopy the patient was administered betamethasone acetate/betamethasone sodium phosphate, intravenously for one hour.  The next day 30 Dec 2020 at 0700AM, she received her mRNA-1273 vaccination. She began to experience her arms aching at site of injection, joint ache and feeling tired after the vaccine. Treatment for the events included tramadol and clovinol, on 31 Dec 2020 at 0630AM.  Action taken with the second dose of mRNA-1273 in response to the event was not reported.    The outcome for the events, arms aching at site of injection, joint ache and feeling tired after the vaccine, are considered resolving.  The reporter's assessment of causality for the events was not provided.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Pt received oral typhoid vaccine #4 dose taken 11/13/2005. Pt experienced dizziness, nausea, stomach pains, 11/13 - 11/14/05 pm and am. Pt diagnosed with colitis 2 years ago did not tell nurse administering medication. recommended she see MP PCP
pt recv vax & the next day pt exp fever of 102, achiness, flu-like sx, nausea & stomach cramps;ER or MD visit was required;pt did not have an allergic rxn to vax;was found to have mononucleosis;fever has cont, fluctuating around 100;